Annovis Bio, Inc. (FRA:07X)
Germany · Delayed Price · Currency is EUR 4.610
+0.390 (9.24%)
At close: Nov 28, 2025
Annovis Bio Company Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia.
It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer’s disease and dementia.
The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Annovis Bio, Inc.
| Country | United States |
| Founded | 2008 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 15 |
| CEO | Maria Maccecchini |
Contact Details
Address: 101 Lindenwood Drive Malvern, Delaware 19355 United States | |
| Phone | 484 875 3192 |
| Website | annovisbio.com |
Stock Details
| Ticker Symbol | 07X |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Maria Maccecchini | Chief Executive Officer |
| Mark Guerin | Chief Financial Officer |